Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
HilleVax, Inc. - Common Stock
(NQ:
HLVX
)
12.79
+0.77 (+6.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
369,590
Open
12.58
Bid (Size)
5.080 (2)
Ask (Size)
13.36 (21)
Prev. Close
12.02
Today's Range
11.99 - 13.20
52wk Range
9.940 - 20.22
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
March 20, 2024
HLVX stock results show that HilleVax beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Recap: HilleVax Q4 Earnings
March 20, 2024
Via
Benzinga
Performance
YTD
-15.91%
-15.91%
1 Month
-23.09%
-23.09%
3 Month
-16.68%
-16.68%
6 Month
+19.53%
+19.53%
1 Year
-8.64%
-8.64%
More News
Read More
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
March 20, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
February 05, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
January 18, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax: Q1 Earnings Insights
May 12, 2023
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Via
Talk Markets
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
January 08, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at Upcoming Investor Conferences
November 01, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 26, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 25, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
Why HilleVax Shares Are Trading Lower
September 20, 2023
Via
Benzinga
HilleVax Announces Pricing of Public Offering of Common Stock
September 19, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 19, 2023
Via
Benzinga
HilleVax Announces Proposed Public Offering of Common Stock
September 19, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 14, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 12, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
May 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
April 25, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
March 17, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Executive Management Appointments and Promotions
January 09, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
HilleVax, Inc.
Via
GlobeNewswire
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
December 05, 2022
From
HilleVax, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.